Research does not estimate vaccine effectiveness against hospitalisation, severe disease, and death.
Two doses of Covaxin, the India-made vaccine, are 50 per cent effective against symptomatic Covid-19, said an independent study by researchers based on real-world assessment . Results of the interim study, which was published in The Lancet Infectious Diseases Journal, showed that two doses of the vaccine manufactured by Bharat Biotech Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns..
The study titled ‘Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study’ assessed 2714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15–May 15, who were symptomatic and underwent RT-PCR test for Covid-19 detection. The researchers, including doctors Manish Soneja, Adil Rashid Khan, Devashish Desai, Ankit Mittal and others, said that they received no funding for the study and protocol for it was approved by AIIMS ethics committee.
Comments
Post a Comment